Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2− advanced breast cancer

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016. J Natl Cancer Cent. 2022;2(1):1–9. doi: 10.1016/j.jncc.2022.02.002
   Google Scholar
• Daily K, Douglas E, Romitti PA, et al. Epidemiology of De novo metastatic breast cancer. Clin Breast Cancer. 2021;21(4):302–308. doi: 10.1016/j.clbc.2021.01.017
   PubMed Web of Science ®Google Scholar
• Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5):dju055. doi: 10.1093/jnci/dju055
   PubMedGoogle Scholar
• Jiang S, Meng Q, Ji F, et al. A bibliometric analysis of metastatic breast cancer: two-decade report (2002-2022). Front Oncol. 2023;13:1229222. doi: 10.3389/fonc.2023.1229222
   PubMedGoogle Scholar
• Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623–1649. doi: 10.1016/j.annonc.2020.09.010
   PubMed Web of Science ®Google Scholar
• Gombos A, Goncalves A, Curigliano G, et al. How I treat endocrine-dependent metastatic breast cancer. ESMO Open. 2023;8(2):100882. doi: 10.1016/j.esmoop.2023.100882
   PubMed Web of Science ®Google Scholar
• Caswell-Jin JL, Plevritis SK, Tian L, et al. Change in survival in metastatic breast cancer with treatment advances: meta-analysis and systematic review. JNCI Cancer Spectr. 2018;2(4):pky062. doi: 10.1093/jncics/pky062
   Web of Science ®Google Scholar
• Burstein HJ, Somerfield MR, Barton DL, et al. Endocrine treatment and targeted therapy for hormone receptor–positive, human epidermal growth factor receptor 2–negative metastatic breast cancer: ASCO guideline update. J Clin Oncol. 2021;39(35):3959–3977. doi: 10.1200/jco.21.01392
   PubMed Web of Science ®Google Scholar
• Elfgen C, Bjelic-Radisic V Targeted therapy in HR+ HER2− metastatic breast cancer: Current clinical trials and their implications for CDK4/6 Inhibitor therapy and beyond treatment options. Cancers (Basel). 2021;13(23):5994. doi: 10.3390/cancers13235994
   PubMed Web of Science ®Google Scholar
• Huppert LA, Gumusay O, Idossa D, et al. Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer. CA Cancer J Clin. 2023;73(5):480–515. doi: 10.3322/caac.21777
   PubMed Web of Science ®Google Scholar
• CSCO. Guidelines of Chinese Society Of Clinical Oncology (CSCO). Diagnosis and treatment of breast cancer guideline 2023. People’s Medical Publishing House Press; 2023.
   Google Scholar
• Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638–3646. doi: 10.1200/jco.2017.75.6155
   PubMed Web of Science ®Google Scholar
• Johnston S, Martin M, Di Leo A, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5(1):5. doi: 10.1038/s41523-018-0097-z
   PubMed Web of Science ®Google Scholar
• Johnston S, O’Shaughnessy J, Martin M, et al. Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups. NPJ Breast Cancer. 2021;7(1):80. doi: 10.1038/s41523-021-00289-7
   PubMed Web of Science ®Google Scholar
• Goetz MP, Toi M, Huober J, et al. LBA15 MONARCH 3: interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC). Ann Oncol. 2022;33(Suppl.S7):S808–S869. doi: 10.1016/j.annonc.2022.08.009
   Google Scholar
• Zhang P, Zhang Q, Tong Z, et al. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2023;24(6):646–657. doi: 10.1016/s1470-2045(23)00172-9
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Eur J Health Econ. 2013;14:367–372. doi: 10.1007/s10198-013-0471-6
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Augustovski F, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Health Policy Open. 2022;3:100063. doi: 10.1016/j.hpopen.2021.100063
   PubMedGoogle Scholar
• Peart O Metastatic Breast Cancer. Radiol Technol. 2017;88(5):519m–539m
   PubMed Web of Science ®Google Scholar
• Early breast cancer trialists’ collaborative group (Ebctcg).Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–1717. doi: 10.1016/s0140-6736(05)66544-0
   PubMed Web of Science ®Google Scholar
• Liu GE, editor. China guidelines for pharmacoeconomic evaluation. China Market Press. 2020.
   Google Scholar
• National Bureau Of Statistics Of China [accessed 2024 Jan 21]. Available from: https://data.stats.gov.cn/search.htm?s=GDP.
   Google Scholar
• Guyot P, Ades AE, Ouwens MJ, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12(1):9. doi: 10.1186/1471-2288-12-9
   PubMed Web of Science ®Google Scholar
• Latimer NR: Survival analysis for economic evaluations alongside clinical trials extrapolation with Patient-Level Data. National Institute for Health and Care Excellence (NICE) Decision Support Unit Technical Support; 2013.
   Google Scholar
• Shenzhen pharmaceutical trading platform [cited 2024 Jan 15]. Available from: https://login.qywgpo.com/login.html
   Google Scholar
• Buehler AM, Castilho G, Dionne P-A, et al. Cost-effectiveness of ribociclib plus letrozole versus palbociclib plus letrozole or letrozole as monotherapy in first-line treatment of postmenopausal women with HR+/HER2− locally advanced or metastatic breast cancer: a Brazilian private payer perspective. Ther Adv Med Oncol. 2021;13:1–16. doi: 10.1177/17588359211000593
   Web of Science ®Google Scholar
• Huang X, Lin S, Rao X, et al. First-line treatment with ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive advanced breast cancer: a cost-effectiveness analysis. Clin Breast Cancer. 2021;21(4):e479–e488. doi: 10.1016/j.clbc.2021.01.019
   PubMed Web of Science ®Google Scholar
• Liao XZ, Shi JF, Liu JS, et al. Medical and non‐medical expenditure for breast cancer diagnosis and treatment in China: a multicenter cross‐sectional study. Asia Pac J Clin Oncol. 2018;14(3):167–178. doi: 10.1111/ajco.12703
   PubMed Web of Science ®Google Scholar
• Mistry R, May JR, Suri G, et al. Cost-effectiveness of Ribociclib plus letrozole versus palbociclib plus letrozole and letrozole monotherapy in the first-line treatment of postmenopausal women with HR+/HER2- advanced or metastatic breast cancer: a U.S. Payer Perspective. J Manag Care Spec Pharm. 2018;24(6):514–523. doi: 10.18553/jmcp.2018.24.6.514
   PubMed Web of Science ®Google Scholar
• Rugo HS, Finn RS, Diéras V, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat. 2019;174(3):719–729. doi: 10.1007/s10549-018-05125-4
   PubMed Web of Science ®Google Scholar
• Stellato D, Thabane ME, Chandiwana D, et al. Cost effectiveness of ribociclib plus a nonsteroidal aromatase inhibitor in pre-/Perimenopausal, HR+ and HER2− advanced breast cancer: a Canadian healthcare perspective. PharmacoEconomics. 2021;39(7):853–867. doi: 10.1007/s40273-021-01028-3
   PubMed Web of Science ®Google Scholar
• Bank of China. Foreign exchange rate [accessed 2023 Dec 1]. Available from: https://www.boc.cn/sourcedb/whpj/
   Google Scholar
• Sprangers MA, Groenvold M, Arraras JI, et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol. 1996;14(10):2756–2768. doi: 10.1200/jco.1996.14.10.2756
   PubMed Web of Science ®Google Scholar
• Goetz MP, Martin M, Tokunaga E, et al. Health-related quality of life in MONARCH 3: abemaciclib plus an aromatase inhibitor as initial therapy in HR+, HER2− advanced breast cancer. Oncology. 2020;25(9):e1346–e1354. doi: 10.1634/theoncologist.2020-0084
   Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–376. doi: 10.1093/jnci/85.5.365
   PubMed Web of Science ®Google Scholar
• Lloyd A, Nafees B, Narewska J, et al. Health state utilities for metastatic breast cancer. Br J Cancer. 2006;95(6):683–690. doi: 10.1038/sj.bjc.6603326
   PubMed Web of Science ®Google Scholar
• Briggs AH, Weinstein MC, Fenwick EAL, et al. Model parameter estimation and uncertainty analysis. Med Decis Making. 2012;32(5):722–732. doi: 10.1177/0272989x12458348
   PubMed Web of Science ®Google Scholar
• IQVIA. Global oncology trends 2021. Available from: https://www.iqvia.com/insights/the-iqvia-institute/reports/global-oncology-trends-2021
   Google Scholar
• Bonetti A, Giuliani J. Implications of drugs with rebate in Europe. Lancet Reg Health Eur. 2021;3:100060. doi: 10.1016/j.lanepe.2021.100060
   PubMedGoogle Scholar
• Zhang Y, Wushouer H, Han S, et al. The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China. BMJ Glob Health. 2021;6(7): e006196 doi: 10.1136/bmjgh-2021-006196
   PubMed Web of Science ®Google Scholar
• Giuliani J, Bonetti A The introduction of a third CDK4/6 inhibitor does not change the cost-effectiveness profile in first and subsequent-lines after progression or relapse during previous endocrine therapy in patients with hormone receptor positive (Hr+)/human epidermal receptor-2 negative (HER-2) advanced or metastatic breast cancer. J Oncol Pharm Pract. 2020;26(6):1486–1491. doi: 10.1177/1078155220934531
   PubMed Web of Science ®Google Scholar
• Masurkar PP, Damgacioglu H, Deshmukh AA, et al. Cost effectiveness of CDK4/6 inhibitors in the first-line treatment of HR+/HER2− metastatic breast cancer in postmenopausal women in the USA. PharmacoEconomics. 2023;41(6):709–718. doi: 10.1007/s40273-023-01245-y
   PubMed Web of Science ®Google Scholar
• Zeng N, Han J, Liu Z, et al. CDK4/6 inhibitors in the first-line treatment of postmenopausal women with HR+/HER2− advanced or metastatic breast cancer: an updated network meta-analysis and cost-effectiveness analysis. Cancers (Basel). 2023;15(13): 3386. doi: 10.3390/cancers15133386
   PubMed Web of Science ®Google Scholar
• Wan X, Zhang Y, Ma J, et al. Ribociclib in hormone-receptor-positive advanced breast cancer: establishing a value-based cost in China. Breast. 2019;43:1–6. doi: 10.1016/j.breast.2018.10.004
   PubMed Web of Science ®Google Scholar